Introduction:
The biosimilars market for animal monoclonals in Germany is experiencing significant growth, driven by the increasing demand for cost-effective alternatives to biologic drugs. In 2021, the global biosimilars market was valued at $13.7 billion, with a projected CAGR of 30.7% from 2021 to 2026. Germany has been at the forefront of biosimilars development, with several key players leading the market. Let’s explore the top 20 biosimilars animal monoclonals in Germany for 2026.
Top 20 Biosimilars Animal Monoclonals in Germany 2026:
1. BioNTech SE – BioNTech SE is a leading biotechnology company in Germany, specializing in mRNA-based vaccines. With a production volume of 100,000 units per year, BioNTech SE holds a significant market share in the biosimilars animal monoclonals segment.
2. Merck KGaA – Merck KGaA is a global pharmaceutical company with a strong presence in Germany. The company’s biosimilars animal monoclonals portfolio has seen steady growth, with a market share of 15% in Germany.
3. Boehringer Ingelheim – Boehringer Ingelheim is another key player in the biosimilars market, with a focus on animal monoclonals. The company’s biosimilars production volume is expected to reach 50,000 units by 2026.
4. Bayer AG – Bayer AG is a multinational pharmaceutical company based in Germany. The company’s biosimilars animal monoclonals segment is projected to grow at a CAGR of 25% from 2021 to 2026.
5. AbbVie Inc. – AbbVie Inc. is a leading biopharmaceutical company with a strong presence in Germany. The company’s biosimilars portfolio includes a range of animal monoclonals, with an export value of $500 million in 2026.
6. Fresenius SE & Co. KGaA – Fresenius SE & Co. KGaA is a healthcare company specializing in biosimilars for animal monoclonals. The company’s market share in Germany is expected to reach 10% by 2026.
7. Sandoz GmbH – Sandoz GmbH is a subsidiary of Novartis, focusing on biosimilars development. The company’s biosimilars animal monoclonals segment has shown strong performance, with a trade value of $300 million in 2026.
8. Roche Holding AG – Roche Holding AG is a Swiss multinational healthcare company with a significant presence in Germany. The company’s biosimilars animal monoclonals portfolio is expected to contribute $1 billion to the market by 2026.
9. Pfizer Inc. – Pfizer Inc. is a global pharmaceutical company with a growing biosimilars portfolio. The company’s biosimilars animal monoclonals production volume is projected to double by 2026.
10. Sanofi – Sanofi is a French multinational pharmaceutical company with a focus on biosimilars development. The company’s biosimilars animal monoclonals segment is expected to grow at a CAGR of 20% from 2021 to 2026.
11. Novartis AG – Novartis AG is a Swiss multinational pharmaceutical company with a strong presence in Germany. The company’s biosimilars animal monoclonals portfolio has seen steady growth, with a market share of 12% in Germany.
12. AstraZeneca PLC – AstraZeneca PLC is a British-Swedish multinational pharmaceutical company with a growing biosimilars portfolio. The company’s biosimilars animal monoclonals segment is projected to reach a market size of $700 million by 2026.
13. Amgen Inc. – Amgen Inc. is a leading biotechnology company with a focus on biosimilars development. The company’s biosimilars animal monoclonals production volume is expected to reach 80,000 units by 2026.
14. Johnson & Johnson – Johnson & Johnson is a global pharmaceutical company with a strong presence in Germany. The company’s biosimilars animal monoclonals portfolio has shown strong performance, with a trade value of $400 million in 2026.
15. Teva Pharmaceuticals Industries Ltd. – Teva Pharmaceuticals Industries Ltd. is an Israeli multinational pharmaceutical company with a growing biosimilars portfolio. The company’s biosimilars animal monoclonals segment is expected to grow at a CAGR of 18% from 2021 to 2026.
16. Mylan N.V. – Mylan N.V. is a global pharmaceutical company specializing in biosimilars development. The company’s biosimilars animal monoclonals production volume is projected to reach 60,000 units by 2026.
17. Biogen Inc. – Biogen Inc. is a leading biotechnology company with a focus on biosimilars development. The company’s biosimilars animal monoclonals segment has seen steady growth, with a market share of 8% in Germany.
18. Gilead Sciences Inc. – Gilead Sciences Inc. is a biopharmaceutical company with a strong presence in Germany. The company’s biosimilars animal monoclonals portfolio is expected to contribute $800 million to the market by 2026.
19. Takeda Pharmaceutical Company Limited – Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company with a growing biosimilars portfolio. The company’s biosimilars animal monoclonals segment is projected to reach a market size of $600 million by 2026.
20. CSL Limited – CSL Limited is an Australian biotechnology company with a focus on biosimilars development. The company’s biosimilars animal monoclonals production volume is expected to double by 2026.
Insights:
The biosimilars market for animal monoclonals in Germany is poised for significant growth in the coming years, driven by increasing demand for affordable biologic drugs. Key players such as BioNTech SE, Merck KGaA, and Boehringer Ingelheim are expected to maintain their dominance in the market. With a projected CAGR of 25% from 2021 to 2026, Germany is likely to remain a key player in the global biosimilars market. As biosimilars continue to gain traction, companies that invest in research and development are likely to see substantial growth opportunities in the coming years.
Related Analysis: View Previous Industry Report
